XCancer

Exploratory, Phase 0 Study of Positron Emission Tomography (PET) Imaging Agent, F-18 RGD-K5

Description:

The purpose of this research study is to get information from volunteers without cancer and patients with cancer who have received a new investigational study agent called, "\[F-18\] RGDK5," to evaluate biodistribution and dosimetry for the study agent and determine F-18 RGD-K5 uptake in angiogenic tumor. the system.

Sponsor:

Unknown Organization

Phase:

Early Phase 1

Contacts:

Michael Yu, MD (PRINCIPAL_INVESTIGATOR)

Government Study Link:

NCT00743353 - Click here to see study on

ClinicalTrials.gov

RGD-K5

Isotope(s):
Target(s):
  • αvβ3
Ligand Class: Peptides
Inclusion
  • For Normal Volunteers
  • Subject is capable of communicating with study personnelFor Cancer Subjects (same first four bullets as 'normals')
  • Subject is ≥ 18 years old at the time of investigational product administration (Subject is male or female of any race / ethnicity)
  • Subject is capable of complying with study procedures
  • Subject or subject's legally acceptable representative provides informed consent
Exclusion

Exclusion Criteria Not Yet Provided